CoronaryAtlas logo
CoronaryAtlas
Chymase
Pathway / Fibrous-cap degradation & rupture

Chymase

CMA1protein

Chymase from activated mast cells degrades fibrous-cap matrix proteins, contributing to cap thinning and rupture in destabilizing plaques.

Pathway placement
Cascade stepFibrous-cap degradation & rupture
Confidencemedium
RationaleMast-cell protease; extracellular-matrix degradation and fibrous-cap remodeling.
Also acts inVascular inflammation, Endothelial activation/erosion
Druggability
DruggableYes
Known drugs / candidates1
Small-molecule tractableYes
Antibody tractableYes
EnsemblENSG00000092009

Type I vs Type II discrimination

ScoresShared / rises in both
R — rupture / Type-I
100
C — confounder / Type-II
67
A — assay feasibility
72
E — evidence strength
53
T1DI (composite)
26
Specificity differential (R−C)+33.3
Confounder panel (Type-II drivers)
1sepsis / systemic inflammationn/a
2anemia / acute blood lossmag 2
3hypovolemia / dehydrationmag 3
4tachyarrhythmiamag 2
5hypoxemia / respiratory failuremag 1
6hypertensive emergencyn/a
7high-demand / peri-operative stressn/a
Coverage: 4/7 confounders with evidence
Tier: deep-scored (abstract-extracted) · 9 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)

Human genetic evidence

0.083
Open Targets association (acute_MI)

Literature evidence(2)